Form 4: Zenas BioPharma Executive Acquires Stock Options
SEC Form 4 Filing
Jennifer A. Fox, Chief Business Officer and Chief Financial Officer of Zenas BioPharma, acquired 8,125 stock options on December 16, 2024.
Summary
- Jennifer A. Fox, the Chief Business Officer and Chief Financial Officer of Zenas BioPharma, was granted 8,125 stock options on December 16, 2024.
- These options have an exercise price of $8.77 per share.
- The options vest over a period of 48 months, with 25% vesting on September 12, 2025, and the remainder vesting in equal monthly installments over the following 36 months.
- The options expire on December 15, 2034.
Sentiment
Score: 7
Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management with shareholder interests. It is not a major event that would drastically change the outlook of the company.
Positives
- The granting of stock options to a key executive like Jennifer A. Fox aligns her interests with the long-term success of the company.
- The vesting schedule encourages continued service and commitment from the executive.
Management Comments
- The form was signed by Chase Jayasekera, Attorney-in-Fact, on behalf of Jennifer A. Fox.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in the biotech industry.
- The vesting schedule of 48 months with a cliff at 12 months is typical for such grants.
- The exercise price of $8.77 is specific to Zenas BioPharma's stock and would need to be compared to other similar companies to assess its relative value.
Stakeholder Impact
- The stock option grant may have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date of stock option grant. |
| 09/12/2025 | Date when 25% of the stock options vest. |
| 12/15/2034 | Expiration date of the stock options. |
| 12/18/2024 | Date the form was signed. |
Keywords
stock options, executive compensation, Zenas BioPharma, insider trading, Jennifer A. Fox, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.